卵巢癌组织肽基精氨酸脱亚胺酶4表达临床意义的研究

Expression and Clinical significance of peptidylarginine deiminase 4 in ovarian tumor tissues

目的:研究肽基精氨酸脱亚胺酸4(PADI4)在不同类型卵巢癌组织中的表达及与临床病理之间的关系。方法:用免疫组织化学法检测和定量分析PADI4在不同类型卵巢癌组织中的表达;用RT-PCR和蛋白质印迹法比较卵巢腺癌(8例)和卵巢囊腺瘤(5例)中的表达水平。结果:PADI4在浆液性囊腺癌(53例,阳性率100%)、黏液性囊腺癌(19例,100%)、子宫内膜型囊腺癌(23例,100%)、透明细胞癌(6例,100%)、内胚窦癌(6例,100%)、鳞状细胞癌(6例,100%)、转移性腺癌(6例,100%)、印戎细胞癌(6例,100%)、无性细胞癌(6例,100%)、生殖细胞癌(6例,100%)和未成熟畸胎瘤(6例,100%)中高表达,但在恶性颗粒细胞瘤(6例)、恶性卵泡膜细胞瘤(6例)以及正常卵巢组织(10例)无表达。在浆液性囊腺癌、黏液性囊腺癌和子宫内膜性囊腺癌中,PADI4表达水平与年龄和临床分期T显著正相关,P<0.01;RT-PCR和蛋白质印迹法证实,PADI4在卵巢腺癌的表达量显著高于在卵巢囊腺瘤中的表达,P=0.001。结论:PADI4可能在多种类恶性卵巢瘤病变过程中起着重要作用。

OBJECTIVE： To investigate the expression of PADI4 in various types of ovarian tumors and its clinical significance. METHODS： The immunohistochemical method was used to analyze the expression of PADI4 in various kinds of ovarian tumors. Real-time quantitative PCR and Western blot was used to determine its transcriptional and translational levels of the enzyme in the tissues. RESULTS： PADI4 was significantly expressed in serous eystadenocarcinoma （n 53, positivity = 100 % ）, endometroid adenocarcinoma （n = 23, 100 % ）, mucinous cystadenoearcinoma （n = 19, 100%）, clear cell cancer （n = 6, 100%）, adenocareinoma metastatic （n = 6, 100%）, sibnet-ring cell carcinoma metastatic （n = 6,100 %）, dysgerminoma （n = 6, 100%）, endodermal sinus tumor （n 6,100%）, squamous cell tumor （n= 6,100%）, germ cell tumors （n 6,100%） andimma ture teratoma （n = 6,100%）, but not in granulosa cell tumor （n=6）, malignant thecoma （n= 6）, and normal tissues （n= 10）. The PADI4 level was positively related to the ages and clinical stages （T） （P〈0.01） in the patients with serous adenocarcinoma, endometroid adenocarcinoma or mucinous adenocarcinoma. RT-PCR and Western blot analysis also confirmed that PA- DI4 had a significantly higher expression in ovarian adenocarcino ma than that in ovarian cystadenoma （P = 0. 001）. CONCLUSION： PADI4 expression may play very important roles in tumorigenisis of most ovary tumor types.